新生儿呼吸窘迫综合征早期应用肺表面活性物质治疗的观察  

Neonatal respiratory distress syndrome of early lung surfactant therapy clinical observation

作　　者：雷东红 闫凡[1] 王利东[1] 迟建秀 葛文文 

机构地区：[1]榆林市第一医院小儿科,陕西榆林718000

出　　处：《临床肺科杂志》2013年第7期1239-1241,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨肺表面活性物质对新生儿呼吸窘迫综合征(NRDS)的治疗效果。方法将100例NRDS患儿随机分为治疗组50例和对照组50例,两组均给予机械通气等常规治疗,治疗组在此基础上给予气管内滴入肺表面活性物质,剂量为100 mg/kg。结果治疗组存活率高于对照组,(P<0.05);治疗组通气时间明显低于对照组(P<0.05);治疗组治疗后血气分析与对照组同项比较,(P均<0.05或<0.01);治疗组治疗后各时段机械通气参数FiO2、VEI、MAP与对照组同项比较,(P均<0.05或<0.01)。结论肺表面活性物质对NRDS疗效满意,值得推广。Objective To evaluate the pulmonary surfactant for neonatal respiratory distress syndrome（NRDS） treatment.Methods： 100 patients were randomly divided into treatment NRDS group of 50 patients and a control group of 50 patients,two groups were given conventional treatment such as mechanical ventilation,on the basis of the treatment group given intratracheal instillation of pulmonary surfactant,a dose of 100 mg / kg.Results： the treatment group survival rate higher than that of control group,（χ2 = 3.679,P〈0.05）;the treatment group ventilation time were significantly lower than the control group（χ2 = 5.88,P〈0.05）;the treatment group after treatment with 6,12,24,48h,PaO2,OI,a/A PO2,blood gas analysis and the control group comparison,（all P〈0.05 or 0.01）;treatment group after treatment in each period of mechanical ventilation parameters FiO2,VEI,MAP and control group comparison,（all P〈0.05 or 0.01）.Conclusion： Pulmonary surfactant on NRDS satisfactory outcome,it is worth promoting.

关 键 词：肺表面活性物质 新生儿 呼吸窘迫综合征 

分 类 号：R722.1[医药卫生—儿科]